financetom
Business
financetom
/
Business
/
Boeing whistleblower found dead of apparent suicide
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Boeing whistleblower found dead of apparent suicide
Mar 12, 2024 8:16 AM

(Reuters) - John Barnett, a former Boeing employee who had reportedly raised concerns about the company's production issues, was found dead of an apparent suicide, according to authorities in South Carolina.

Barnett had worked at Boeing ( BA ) for 32 years before leaving the company in 2017, according to the BBC, which previously reported on his efforts to raise issues about the company's production issues.

The 62-year-old died of a self-inflicted gunshot wound, the Charleston County coroner's office in South Carolina confirmed on Tuesday. The Charleston City police are investigating, the coroner's office said, without giving any other details.

Boeing ( BA ), in a statement, said: "We are saddened by Mr. Barnett's passing, and our thoughts are with his family and friends."

Barnett's attorney, Brian Knowles, did not respond to requests for comment. He told the publication Corporate Crime Reporter that Barnett had been in the middle of a deposition in a whistleblower lawsuit in Charleston related to production of the 787 Dreamliner plane.

Barnett had spoken to media outlets following the Jan. 5 incident on a Boeing 737 MAX 9 plane, when a panel blew out while the flight was in mid-air, exposing passengers to the outside air that required an emergency landing.

Boeing ( BA ) has since had to reckon with a full-blown crisis around its safety and quality standards. Its production has been curbed by U.S. regulators, leading to delivery delays across the aerospace industry.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Logility Supply Chain Solutions Says Bidder Pulled Unsolicited Cash Takeover Proposal of $15 a Share
Logility Supply Chain Solutions Says Bidder Pulled Unsolicited Cash Takeover Proposal of $15 a Share
Mar 10, 2025
10:02 AM EDT, 03/10/2025 (MT Newswires) -- Logility Supply Chain Solutions ( LGTY ) said Monday that the unsolicited, non-binding proposal to acquire all of its outstanding common shares for $15 per share in cash has been withdrawn by the bidder. The company confirmed receiving the proposal on Friday and did not disclose any reason for the withdrawal. Logility said...
Alliant Energy Names Patrick Allen as New Board Chair
Alliant Energy Names Patrick Allen as New Board Chair
Mar 10, 2025
10:05 AM EDT, 03/10/2025 (MT Newswires) -- Alliant Energy ( LNT ) said Monday that Patrick Allen has been selected to be the new independent chair of the utility company's board of directors, effective after Alliant's next annual shareholders' meeting in May. Allen will succeed John Larsen, who retired as executive board chair earlier this year after 36 years at...
Baird Medical Receives Indonesian Regulatory Approval for Microwave Ablation Equipment
Baird Medical Receives Indonesian Regulatory Approval for Microwave Ablation Equipment
Mar 10, 2025
10:05 AM EDT, 03/10/2025 (MT Newswires) -- Baird Medical Investment ( BDMD ) said Monday it has received regulatory approval in Indonesia for its Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle. The company's medical instruments use microwave ablation technology to target abnormal tissue using focused microwave energy with little effect on nearby areas to...
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
Mar 10, 2025
On Monday, Protagonist Therapeutics, Inc ( PTGX ). announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC). The study conducted by Protagonist’s collaboration partner, Johnson & Johnson ( JNJ ), met its primary endpoint of clinical response in all icotrokinra dose groups evaluated. Additionally, the study demonstrated clinically meaningful...
Copyright 2023-2026 - www.financetom.com All Rights Reserved